@article{c51940f3f781475e9b2fcd74b49bb0d9,
title = "Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir",
abstract = "The objectives of the study were to examine the clinical significance of cytomegalovirus (CMV) culture results and drug susceptibilities in CMV isolates from patients with AIDS-related CMV retinitis. Blood and urine for CMV culture were obtained from 207 patients with newly diagnosed CMV retinitis who were enrolled in a randomized trial comparing foscarnet and ganciclovir. Culture positive rates at baseline were 45% and 71% for blood and urine, respectively. Rates decreased 3-to 10-fold after initiation of either treatment. Mortality was related to both positive baseline blood and urine cultures; adjusted relative risks were 1.97 and 2,03, respectively. Positive blood cultures at baseline were associated with more rapid retinitis progression. Drug-resistant CMV was found, over comparable follow-up periods on assigned treatment, in 4 of 8 ganciclovir-assigned patients with persistent viremia and 0 of 5 foscarnet-assigned patients with persistent viremia. Results of virologic assays of blood appear to be associated with clinical outcome of CMV retinitis.",
author = "Jabs, {Douglas A.} and Mark Jacobson",
note = "Funding Information: Financial support: Cooperative agreements from the National Eye Institute to The John Hopkins University School of Medicine (U10 EY-08052) and School of Hygiene and Public Health (U10 EY-08057) and the University of Wisconsin School of Medicine (U10 EY-08067); National Center for Research Resources through General Clinical Research Center grants: 5M01 RR-00350 (Baylor College of Medicine); 5M01 RR-00035 and 5M01 RR-00722 (The John Hopkins University); 5M01 RR-05096 (Louisiana State University, Tu-lane); 5M01 RR-00071 (Mt. Sinai Medical Center); 5M01 RR 00047 (New York Hospital-Cornell Medical Center); 5M01 RR-00096 (New York University); 5M01 RR-00048 (Northwestern University); 5M01 RR-00865 (University of California, Los Angeles); 5M01 RR-00083 (University of California, San Francisco); and 5M01 RR-05280 (University of Miami). Support was also provided by National Institute of Allergy and Infectious Diseases through cooperative agreements U01 AI-27668 (The Johns Hopkins University); U01 AI-27674 (Louisiana State University, Tulane); U01 AI-27669 (Memorial Sloan-Kettering Cancer Institute) and U01 AI-25917 (New York Hospital-Cornell Medical Center); U01 AI-27667 (Mount Sinai Medical Center); U01 AI-27665 (New York University); U01 AI-25915 (Northwestern University); U01 AI-27660 (University of California, Los Angeles); U01 AI-27670 (University of California, San Diego); U01 AI-27663 (University of California, San Francisco); and U01 AI-25831 (University of Massachusetts). Funding was also provided by Astra Pharmaceutical Products, Inc. (Westborough, MA). Drugs were provided by Astra Pharmaceutical Products, Inc., Burroughs Wellcome, Co., and Syntex Research. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "1997",
doi = "10.1086/514039",
language = "English (US)",
volume = "176",
pages = "50--58",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",
}